We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Obesity and diabetes have become a problem for developed world countries. To address the global rise of these issues, this company is pursuing a dual-gene therapy strategy using proprietary To...
CannabisNewsWire Editorial Coverage: The emergence of a legal recreational cannabis sector has drawn attention away from the medical cannabis market. However, many companies continue to move...
NetworkNewsWire Editorial Coverage: As the legal cannabis market continues to grow, new deals are creating opportunities for a range of companies and an influx of investments. PreveCeutical...
NetworkNewsWire Editorial Coverage: Hydrogels have been in limited commercial use for more than two decades. However, advancements in drug delivery, and thus hydrogel technology, are driving rapid...
NetworkNewsWire Editorial Coverage: Pain is a wide-ranging complex medical condition that can be both physically debilitating and mentally destabilizing. Whether acute or chronic, caused by...
NetworkNewsWire Editorial Coverage: The rapidly growing cannabis industry has spawned a range of diverse companies focusing on innovative technologies for cannabis cultivation, as well as the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0021 | 18.75 | 0.0112 | 0.0145 | 0.0112 | 19482 | 0.01249321 | CS |
4 | 0.00226 | 20.4710144928 | 0.01104 | 0.01525 | 0.01 | 40656 | 0.01185545 | CS |
12 | -0.00395 | -22.8985507246 | 0.01725 | 0.02 | 0.01 | 40457 | 0.01430772 | CS |
26 | -0.0029 | -17.9012345679 | 0.0162 | 0.02 | 0.01 | 48847 | 0.0156292 | CS |
52 | -0.0057 | -30 | 0.019 | 0.0228 | 0.01 | 44766 | 0.01653008 | CS |
156 | -0.001705 | -11.3628790403 | 0.015005 | 0.0299 | 0.01 | 60675 | 0.0195732 | CS |
260 | -0.0075 | -36.0576923077 | 0.0208 | 0.1 | 0.0005 | 250056 | 0.03495956 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions